有的患者通过先进治疗重获新生，有的却在治疗过程中遭遇意想不到的“副作用陷阱”。今天，我要和大家分享一个让我震惊的消息：一项最新研究揭示，Dupilumab（度普利尤单抗）——一种被誉为“特应性皮炎杀手”的生物制剂，竟然可能增加银屑病的发生风险！这不是 ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

这项发表在权威期刊的队列研究揭示了免疫治疗领域的重要发现。研究人员通过TriNetX全球数据库，对214,430例成人特应性皮炎(AD)患者进行3年随访，比较Dupilumab（一种靶向IL-4Rα的单抗）与其他系统性药物（如糖皮质激素、甲氨蝶呤等）的银屑病发生风险。

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

智通财经APP获悉，再生元(REGN.US)和赛诺菲(SNY.US)联合开发的重磅疗法Dupixent(dupilumab)获美国FDA批准，用于治疗大疱性类天疱疮(BP)成人患者。根据新闻稿，Dupixent是获美国FDA批准的首款BP疗法。据悉， ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

Bio-Thera Solutions & SteinCares expand partnership to commercialize biosimilars to treat inflammatory diseases across Latin America: Guangzhou, China Thursday, June 26, 2025, 12: ...